Healthcare and life sciences lawyers will likely have plenty of work in 2022 thanks to pending legislative and regulatory actions throughout the healthcare, health insurance, and drug and device industries.
According to this Law360 article, surprise billing, abortion and drug pricing are some of the major issues facing lawmakers and regulators in the year ahead. McDermott Partner Michael Ryan noted that changes to the Medical Device User Fee Amendments (MDUFA) also could be in order.
President Biden’s July 9, 2021, Executive Order—which seeks to increase competition throughout the American economy—takes aim at prescription drug prices. In this article, published in Law360, McDermott partner Emily Jane Cook says Biden’s focus on drug prices is unsurprising given the “significant public interest and frustration” with drug costs.
On 4 May 2015, the National Development and Reform Commission, the National Health and Family Planning Commission, and four other ministerial departments of the Chinese central government jointly published the Notice of Promoting the Reform of Drug Pricing. As of 1 June 2015, the price ceiling for most drugs has been eliminated, with the intention of reducing government intervention in drug pricing and adopting a market-driven pricing system.
Subscribe
